Distinct disciplines, integrated deliberately.
Validation, coding, coverage, commercialization, and collections are separate problems. DMC works across all five and keeps context intact between them.
- 01 — Assay
Assay Readiness & Validation
Analytical-validation planning, documentation, scientific readiness reviews, gap assessment, and coordination with laboratory and scientific teams to prepare an assay for commercialization. - 02 — Code
Coding & Reimbursement Strategy
Coding pathway evaluation — including PLA/CPT where applicable — plus the documentation, evidence, and reimbursement strategy needed to support payment. Obtaining a code does not by itself establish coverage or payment; we plan each explicitly. - 03 — Cover
Coverage & Market Access
Payer strategy, evidence requirements, coverage planning, MolDX-related considerations where applicable, and reimbursement readiness ahead of launch. - 04 — Commercialize
Commercialization & Adoption
Go-to-market strategy, physician adoption, health-system relationships, channel partnerships, commercialization planning, and enterprise contracting. - 05 — Collect
Specialized Laboratory Revenue Cycle
Eligibility, prior authorization where applicable, coding integrity, claim scrubbing, denials, appeals, payer follow-up, reconciliation, and collections.
We understand the reimbursement and scientific context behind the claim — not just the billing transaction.
Diagnostic revenue cycle is not general medical billing. Molecular, genomic, anatomic pathology, and toxicology claims fail for reasons that generic billing operations rarely diagnose.
- 01
Eligibility & prior authorization
Payer-specific workflows and medical-necessity documentation where prior authorization applies. - 02
Coding integrity
CPT, PLA, modifier, Z-code, and CCI rule support aligned to the specific assays on your menu. - 03
Claim pre-scrubbing
Payer-plan and state-level edits applied before submission to reduce avoidable rework. - 04
Denials & appeals
Root-cause review and payer-by-payer appeal workflows built around diagnostic policy language. - 05
Payer follow-up & reconciliation
Structured follow-up, payment posting, reconciliation, and variance review against expected reimbursement. - 06
Revenue optimization
Net revenue per test, per payer, and per assay — with the reimbursement strategy behind the numbers.
Proven RCM infrastructure underneath. Proprietary diagnostics intelligence on top.
Available today through established technology partners: automated order ingestion and demographic discovery; eligibility, prior authorization, and medical-necessity workflows; payer-plan and state-level claim pre-scrubbing; CPT, modifier, Z-code, and CCI rule support; reconciliation and cash posting; and automated claim follow-up.
The diagnostics-specific intelligence layer is in development. DMC does not own the underlying third-party RCM infrastructure, and coding and reimbursement decisions remain under human review. Technology supports expert judgment; it does not guarantee payer outcomes.
Where regulatory, laboratory, and partnership work fits.
These capabilities exist in service of the continuum — not as separate practice silos.
- 01
Regulatory & quality coordination
CLIA, CAP, and state licensure readiness, quality systems, and inspection preparedness — with FDA, EU, legal, and technical submission work coordinated through appropriate specialists where required. - 02
Laboratory operations
Operational leadership and improvement for high-complexity laboratories, including multi-site coordination and menu expansion. - 03
Laboratory & channel network
A curated, growing network of laboratory, reimbursement, scientific, and commercialization partners that can be assembled around a specific program. - 04
Strategic partnerships
Enterprise relationships, joint ventures, and contracting structures that support long-term diagnostic commercialization.